Biopsy of Oral Tissue — Soft (Incisional) Template

Incisional biopsy of oral tissue - hard.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Site: Site/tooth area
Lesion description: Lesion description
Size: Size
Duration: Duration

Consent: Consent/PARQ reviewed; signed/verbally obtained

Biopsy code support: Incisional/excisional/cell collection
Clinical appearance: Color, borders, ulceration, induration, symptoms
Pre-op photo/size/location: Photo taken; lesion size and anatomical location
Removal method/pathology: Method of tissue removal; lab sent; pathology result follow-up plan

Radiographs/images: Radiographs/images reviewed/taken and findings

Anesthesia: Anesthetic used
Carps: Carpules/amount

Procedure:
Representative sample obtained.
Specimen includes lesion margin and normal tissue.
Hemostasis achieved.
Sutured with: Suture material/size

Specimen placed in formalin.
Sent to pathology lab: Pathology lab/specimen details

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.

Results to be discussed at follow-up.

NV: Next visit

Documentation requirements

Biopsies are among the most consequential procedures in a general practice — the chart and the pathology report together are the medico-legal record that drives downstream cancer care. The oral surgery chapter and ADA biopsy guidance both call out a specific documentation set; missing any of these items invites denials and, more seriously, malpractice exposure if a malignancy is later diagnosed. A defensible D7286 note must contain:

• Date of service and start/stop time — biopsies often qualify for medical-payor cross-coding where time supports the level of work; chart time even when the dental claim does not require it.
• Medical and dental history reviewed — including anticoagulant therapy (warfarin, DOACs, antiplatelets), bleeding disorders, immunosuppression, anti-resorptive or antiangiogenic therapy (MRONJ risk), prior head/neck radiation, prior oral cancer, tobacco and alcohol use (pack-years and drinks/week), and HPV history. These elements drive risk stratification and pathologist interpretation.
• Vitals — pre-op BP and pulse; post-op vitals when extended visit, sedation, or significant anesthetic volume. Many state boards require vitals on operative visits.
• Chief complaint and history of present illness — when the patient first noticed the lesion, any change in size / color / symptoms over time, prior treatment attempted (chlorhexidine rinse, antifungal, removal of irritation source), and whether the lesion has recurred.
• Site / anatomical location — specific named site (e.g., "right lateral border of tongue, mid-third"), not a generic "tongue lesion." Anatomical precision is essential because a re-biopsy or excision must find the same site.
• Lesion description — objective findings — color, size in millimeters in two or three dimensions, shape, borders (well-defined vs. ill-defined, rolled, indurated), surface (smooth, ulcerated, papillary, verrucous, granular), consistency (soft, firm, indurated, fluctuant), mobility, fixation to underlying tissue, base, and any surrounding satellite lesions. Avoid conclusory language ("benign-appearing fibroma") in favor of objective findings; the pathologist provides the diagnosis.
• Duration — how long the lesion has been present, with special attention to lesions persisting >14 days (a recognized red-flag duration for oral cancer screening).
• Symptoms — pain, paresthesia, bleeding, taste change, dysphagia, ill-fitting denture, or asymptomatic.
• Risk factors specific to this patient — tobacco (pack-years), alcohol (drinks/week), HPV history, prior oral cancer, immunosuppression, head/neck radiation. These belong in the biopsy note even if they are also in the medical history.
• Pre-op intraoral photograph(s) — at least one photograph documenting the lesion, ideally with a millimeter ruler in frame and one wide-field view for anatomical context. explicitly lists pre-operative intraoral photos under biopsy documentation requirements; absence is a frequent audit and malpractice finding.
• Clinical impression / differential — the clinician's working differential before pathology (e.g., "differential includes traumatic ulcer vs. squamous cell carcinoma vs. lichenoid mucositis"). This shows the biopsy was indicated and grounds the pathologist's interpretation.
• Consent / PARQ — signed or verbally obtained. PARQ should cover the rationale (need for histopathologic diagnosis), alternatives (continued observation, referral to oral surgery / OMFS), risks (bleeding, infection, scarring, paresthesia for tongue / floor of mouth / mental nerve sites, recurrence, need for additional surgery if pathology shows malignancy or unclear margins), and the explicit understanding that a pathology report will be issued and reviewed with the patient.
• Biopsy method (incisional) — explicit confirmation that the procedure is incisional (partial removal), to align the chart with the D7286 code. Note the instrument used (scalpel #15 / #11, 3 mm or 4 mm punch, laser, electrosurgery). Industry guidance notes the method does not change the code or the fee.
• Anesthesia — topical agent, local anesthetic agent and concentration, vasoconstrictor, technique (block / infiltration), and carpule count. For tongue / floor-of-mouth / lip biopsies, regional blocks are common; document landmarks and negative aspirations.
• Specimen capture — confirmation that the sample includes the lesion margin and a small rim of clinically normal tissue (the ADA biopsy guidance and oral pathology references describe the lesion-edge margin as essential for an interpretable specimen). Note specimen approximate size in mm.
• Hemostasis — how it was achieved (pressure, electrocautery, sutures, hemostatic agent). For patients on anticoagulants, document specific measures taken.
• Suture material and size — type (chromic gut, plain gut, silk, polyglycolic acid, polypropylene), gauge (4-0, 5-0, 6-0), and number of sutures placed. Resorbable sutures are typical for intraoral biopsies.
• Specimen handling — placed in 10% neutral buffered formalin (or saline / Michel's medium for direct immunofluorescence on suspected vesiculobullous lesions, or fresh on saline gauze for flow cytometry on suspected lymphoid lesions). Container labeled with patient name, DOB, site, and date.
• Pathology laboratory and requisition — name of the laboratory (e.g., Pacific Oral and Maxillofacial Pathology, Tufts OMFS Pathology, ProPath, regional oral pathology service), accession or specimen tracking number when available, and what was sent on the requisition (clinical history, site, lesion description, clinical impression, clinician contact). the ADA both flag specimen-handling and labeling as the most common preventable cause of inconclusive pathology results.
• Pathology-result follow-up plan — explicit documentation of how the result will be communicated (phone call, patient portal message, in-person follow-up visit), the expected turnaround time (typically 5-10 business days), and what the next step is depending on the result (definitive excision, referral to oral surgery / ENT / oncology, observation, no further treatment). The plan to file the pathology report in the chart upon receipt is itself part of the record.
• Complications — explicit "None" or describe (excessive bleeding, syncope, anesthesia complication, accidental sampling of adjacent structures).
• Patient tolerance and response — tolerated well, mild discomfort managed, etc. Note post-op vitals if extended visit or sedation.
• Post-op instructions — soft diet 24-48 hours, avoid spicy / hot / acidic foods, gentle salt-water rinses starting tomorrow, expected mild bleeding for 24 hours, NSAID regimen, return precautions for prolonged bleeding / increasing pain / swelling / fever / numbness, suture removal plan if non-resorbable.
• Next visit — follow-up specifically scheduled to review the pathology report and discuss findings with the patient. the ADA's accurate-reporting-of-biopsies guidance both flag the documented results-discussion visit as an essential closing element.
• Provider signature and assistant initials — required.

Two phrases that defuse the most common biopsy audit and malpractice questions: an explicit "specimen sent to [named pathology lab] on [date]; results to be reviewed with patient at follow-up on [date]" line, and an explicit "pathology report will be filed in chart upon receipt and patient will be notified of results" line. Together they document the closed-loop responsibility that biopsy procedures carry.

Common denial reasons

D7286 has its own denial pattern, distinct from extraction or restorative codes. The most frequent reasons it is denied, downgraded, or recouped:

• Submitted to dental insurance only, without medical cross-coding — dental payors rarely reimburse biopsies as the primary payor; the carrier denies and refers to medical. The standard workflow is medical primary, dental secondary.
• Claim submitted before the pathology report is received — carriers commonly defer or deny pending the report. ADA both recommend holding the claim until pathology is in hand.
• Pathology specimen never sent / not documented — D7286 implies a specimen is submitted to a pathology laboratory. A chart that records lesion removal but no pathology submission supports a recode to an excision code (D7411, D7412, D7960, etc.) or denial as inappropriate code selection.
• Specimen-handling errors — formalin not used (or wrong fixative for the suspected diagnosis), unlabeled container, missing requisition, wrong site labeled. The pathologist's report comes back as "specimen non-diagnostic" or "tissue insufficient for evaluation," which both undermines the medical-necessity claim and creates malpractice exposure.
• No pre-op intraoral photograph documented — increasingly cited by reviewers as a missing required element. explicitly lists pre-op photos under biopsy documentation requirements.
• Lesion description reads as conclusory rather than objective — "benign-appearing fibroma" or "obvious mucocele" without objective findings (color, size, texture, induration, duration) supports a recode to an excision code rather than a diagnostic biopsy.
• No clinical impression / differential documented — the chart should explain why a biopsy was indicated. Absent a differential or working diagnosis, reviewers question medical necessity.
• Same-DOS billing with same-lesion excision code (D7287, D7411, D7412) — automatic edit rejection. When the entire lesion is removed, only the excision code is reported.
• Wrong code for the specimen type — billing D7286 (soft) for a hard / osseous specimen, or billing D7285 (hard) for soft tissue, is a fundamental code-selection error and triggers immediate denial. Verify the current CDT descriptor; the soft / hard pairing was reorganized in recent editions.
• Cosmetic framing in the chart — language suggesting the indication is appearance rather than diagnosis (e.g., "patient wants this lump removed because it looks bad") supports a denial as cosmetic / non-covered.
• Frenectomy, fibroma, or pericoronal-tissue removal billed as D7286 — when the procedure was definitive treatment of a non-suspicious anatomical structure, the appropriate code is the excision code (D7960 frenulectomy, D7971 excision of pericoronal tissue, D7411 excision of benign lesion ≥1.25 cm, D7410 <1.25 cm), not D7286. Billing D7286 because a specimen happened to be sent does not convert the procedure into a diagnostic biopsy if the indication was excisional from the outset.
• Multiple biopsies on the same lesion same DOS — only one biopsy code per lesion per date. Distinct lesions at distinct sites can each be billed.
• No pathology-result follow-up plan documented — increasingly flagged as a missing closing element. The closed-loop responsibility (results filed in chart, patient notified, next step determined) is part of the standard of care.
• PARQ missing the malignancy-discovery contingency — consent that does not include the possibility of malignancy and the need for additional treatment supports a malpractice claim if pathology shows cancer.
• Practice-level audit triggers — elevated D7286 frequency without corresponding pathology-lab claims, biopsy-to-excision ratios that read as upcoded excisions, and absent follow-up encounters all draw chart audits. Several state OIG dental fraud reports cite biopsy patterns.

Related templates